Calcium dobesilate prevents the oxidative stress and inflammation induced by diabetes in the retina of db/db mice

Journal of Diabetes and its Complications

Volumn 31, Issue 10, 2017, Pages 1481-1490

  Bogdanov, Patricia ^a,b   Solà Adell, Cristina ^a,b   Hernández, Cristina ^a,b   García Ramírez, Marta ^a,b   Sampedro, Joel ^a   Simó Servat, Olga ^a   Valeri, Marta ^c   Pasquali, Christian ^d   Simó, Rafael ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^d Vifor (International) Inc   (Switzerland)

Author keywords

Calcium dobesilate; db db mouse; Diabetic retinopathy; Inflammation; Oxidative stress; Retinal endothelial cells

Indexed keywords

BIOLOGICAL MARKER; DOBESILATE CALCIUM; HYDROETHIDINE; I KAPPA B KINASE ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MALONALDEHYDE; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR; ANTIOXIDANT; CYTOKINE; I KAPPA B KINASE; IKK2 PROTEIN, RAT; NEUROPROTECTIVE AGENT; NONSTEROID ANTIINFLAMMATORY AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DB/DB MOUSE; DIABETIC RETINOPATHY; DOSE RESPONSE; ENDOTHELIUM CELL; ENZYME PHOSPHORYLATION; EXPERIMENTAL DIABETES MELLITUS; EYE PROTECTION; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RETINA CELL; TREATMENT DURATION; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL CULTURE; COMPLICATION; CROSS BREEDING; DRUG EFFECT; IMMUNOLOGY; METABOLISM; MUTANT MOUSE STRAIN; PATHOLOGY; PHOSPHORYLATION; PROTEIN PROCESSING; RANDOMIZATION; RETINA; RETINITIS; TRANSGENIC MOUSE;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIOXIDANTS; BIOMARKERS; CALCIUM DOBESILATE; CELLS, CULTURED; CROSSES, GENETIC; CYTOKINES; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; HUMANS; I-KAPPA B KINASE; MALE; MICE, MUTANT STRAINS; MICE, TRANSGENIC; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; RANDOM ALLOCATION; RETINA; RETINITIS;

EID: 85028331178     PISSN: 10568727     EISSN: 1873460X     Source Type: Journal    
DOI: 10.1016/j.jdiacomp.2017.07.009     Document Type: Article

References (47)

1. Cheung, N., Mitchell, P., Wong, T.Y., Diabetic retinopathy. Lancet 376 (2010), 124–136.
2. Yau, J.W., Rogers, S.L., Kawasaki, R., Lamoreux, E.L., Kowalski, J.W., Bek, T., et al. Global prevalence and majority risk factors of diabetic retinopathy. Diabetes Care 35 (2012), 556–564.
3. Simó, R., Hernández, C., Intravitreous anti-VEGF for diabetic retinopathy: hopes and fears for a new therapeutic strategy. Diabetologia 51 (2008), 1574–1580.
4. Simó, R., Hernández, C., Novel approaches for treating diabetic retinopathy based on recent pathogenic evidence. Prog Retin Eye Res 48 (2015), 160–180.
5. Keenan, H.A., Costacou, T., Sun, J.K., Doria, A., Cavellerano, J., Coney, J., et al. Clinical factors associated with resistance to microvascular complications in diabetic patients of extreme disease duration: the 50-year medalist study. Diabetes Care 30 (2007), 1995–1997.
6. Moss, S.E., Klein, R., Klein, B.E., Ten-year incidence of visual loss in a diabetic population. Ophthalmology 101 (1994), 1061–1070.
7. Patel, A., MacMahon, S., Chalmers, J., Neal, B., Billot, L., Woodward, M., et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358 (2008), 2560–2572.
8. The Diabetes Control and Complications Trial Research Group, Clustering of long-term complications in families with diabetes in the diabetes control and complications trial. Diabetes 46 (1997), 1829–1839.
9. Zhang, L., Krzentowski, G., Albert, A., Lefebvre, P.J., Risk of developing retinopathy in diabetes control and complications trial type 1 diabetic patients with good or poor metabolic control. Diabetes Care 24 (2001), 1275–1279.
10. Lachin, J.M., Genuth, S., Nathan, D.M., Zinman, B., Rutledge, B.N., DCCT/EDIC Research Group, Effect of glycemic exposure on the risk of microvascular complications in the diabetes control and complications trial—revisited. Diabetes 57 (2008), 995–1001.
11. The Diabetes Control and Complications Trial Research Group, The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes 44 (1995), 968–983.
12. Joussen, A.M., Poulaki, V., Le, M.L., Koizumi, K., Esser, C., Janicki, H., et al. A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J 18 (2004), 1450–1452.
13. Tang, J., Kern, T.S., Inflammation in diabetic retinopathy. Prog Retin Eye Res 30 (2011), 343–358.
14. Kowluru, R.A., Mishra, R., Oxidative stress mitochondrial damage and diabetic retinopathy. Biochim Biophys Acta 1852 (2015), 2474–2483.
15. Sévin, R., Cuendet, J.-F., Cinq annés d'expérimentation avec le dobésilate de calcium dans le traitement des rétinopathies. Schweiz Ophthalmol (Basel) 170 (1975), 232–238.
16. Zhang, X., Liu, W., Wu, S., Jin, J., Wang, N., Calcium-dobesilate for diabetic retinopathy: a systematic review and meta-analysis. Sci China Life Sci 58 (2015), 101–107.
17. Leite, E.B., Mota, M.C., Faria de Abreu, J.R., Cunha-Vaz, J.G., Effect of calcium dobesilate on the blood-retinal barrier in early diabetic retinopathy. Int Ophthalmol 24 (1990), 81–88.
18. Ribeiro, M.L., Seres, A.I., Carneiro, A.M., Stur, M., Zourdani, A., Caillon, P., et al. Effect of calcium dobesilate on progression of early diabetic retinopathy: a randomised double-blind study. Graefes Arch Clin Exp Ophthalmol 244 (2006), 1591–1600.
19. Bogdanov, P., Corraliza, L., Villena, J.A., Carvalho, A.R., Garcia-Arumí, J., Ramos, D., et al. The db/db mouse: a useful model for the study of diabetic retinal neurodegeneration. PLoS One, 16, 2014, e97302.
20. Solà-Adell, C., Bogdanov, P., Hernández, C., Sampedro, J., Valeri, M., García-Ramirez, M., et al. Calcium dobesilate prevents neurodegeneration and vascular leakage in experimental diabetes. Curr Eye Res, 2017, 1–14, 10.1080/02713683.2017.1302591 [Epub ahead of print].
21. Barnes, D.E., DNA damage: air-breaks. Curr Biol 12 (2002), R262–R264.
22. Jarrett, S.G., Lin, H., Godley, B.F., Boulton, M.E., Mitochondrial DNA damage and its potential role in retinal degeneration. Prog Retin Eye Res 27 (2008), 596–607.
23. Kanwar, M., Chan, P.S., Kern, T.S., Kowluru, R.A., Oxidative damage in the retinal mitochondria of diabetic mice: possible protection by superoxide dismutase. Invest Ophthalmol Vis Sci 48 (2007), 3805–3811.
24. Kowluru, R.A., Diabetic retinopathy: mitochondrial dysfunction and retinal capillary cell death. Antioxid Redox Signal 7 (2005), 1581–1587.
25. Stuart, J.A., Brown, M.F., Mitochondrial DNA maintenance and bioenergetics. Biochim Biophys Acta 1757 (2006), 79–89.
26. Trudeau, K., Molina, A.J., Guo, W., Roy, S., High glucose disrupts mitochondrial morphology in retinal endothelial cells, implications for diabetic retinopathy. Am J Pathol 177 (2010), 447–455.
27. Van Houten, B., Woshner, V., Santos, J.H., Role of mitochondrial DNA in toxic responses to oxidative stress. DNA Repair (Amst) 5 (2005), 145–152.
28. El-Asrar, A.M., Nawaz, M.I., Kangave, D., Geboes, K., Ola, M.S., Ahmad, S., et al. High-mobility group box-1 and biomarkers of inflammation in the vitreous from patients with proliferative diabetic retinopathy. Mol Vis 17 (2011), 1829–1838.
29. Hernández, C., Segura, R.M., Fonollosa, A., Carrasco, E., Francisco, G., Simó, R., Interleukin-8, monocyte chemoattractant protein-1 and IL-10 in the vitreous fluid of patients with proliferative diabetic retinopathy. Diabet Med 22 (2005), 719–722.
30. Xu, H., Chen, M., Forrester, J.V., Para-inflammation in the aging retina. Prog Retin Eye Res 28 (2009), 348–368.
31. Joussen, A.M., Murata, T., Tsujikawa, A., Kirchhof, B., Bursell, S.E., Adamis, A.P., Leukocyte-mediated endothelial cell injury and death in the diabetic retina. Am J Pathol 158 (2001), 147–152.
32. Simó-Servat, O., Hernández, C., Simó, R., Usefulness of the vitreous fluid analysis in the translational research of diabetic retinopathy. Mediators Inflamm, 872978, 2012.
33. Aveleira, C.A., Lin, C.M., Abcouwer, S.F., Ambrósio, A.F., Antonetti, D.A., TNF-α signals through PKCz/NF-kB to alter the tight junction complex and increase retinal endothelial cell permeability. Diabetes 59 (2010), 2872–2882.
34. Huang, L., Zhang, R., Wu, J., Increased susceptibility to acute kidney injury due to endoplasmic reticulum stress in mice lacking tumor necrosis factor-a and its receptor 1. Kidney Int 79 (2011), 613–623.
35. Maruo, N., Morita, I., Shirao, M., Murota, S., IL-6 increases endothelial permeability in vitro. Endocrinology 131 (1992), 710–714.
36. Ghasemi, H., Ghazanfari, T., Yaraee, R., Faghihzadeh, S., Hassan, Z.M., Roles of IL-8 in ocular inflammations: a review. Ocul Immunol Inflamm 19 (2011), 401–412.
37. Rangasamy, S., McGuire, P.G., Franco Nitta, C., Monickaraj, F., Oruganti, S.R., Das, A., Chemokine mediated monocyte trafficking into the retina, role of inflammation in alteration of the blood-retinal barrier in diabetic retinopathy. PLoS One, 9, 2014, e108508.
38. Kern, T.S., Contributions of inflammatory processes to the development of the early stages of diabetic retinopathy. Exp Diabetes Res, 95103, 2007.
39. Kowluru, R.A., Koppolu, P., Chakrabarti, S., Chen, S., Diabetes-induced activation of nuclear transcriptional factor in the retina, and its inhibition by antioxidants. Free Radic Res 37 (2003), 1169–1180.
40. Zheng, L., Szabó, C., Kern, T.S., Poly(ADP-ribose) polymerase is involved in the development of diabetic retinopathy via regulation of nuclear factor-κB. Diabetes 53 (2004), 2960–2967.
41. Romeo, G., Liu, W.-H., Asnaghi, V., Kern, T.S., Lorenzi, M., Activation of nuclear factor-κB induced by diabetes and high glucose regulates a proapoptotic program in retinal pericytes. Diabetes 51 (2002), 2241–2248.
42. Zheng, L., Howell, S.J., Hatala, D.A., Huang, K., Kern, T.S., Salicylate-based anti-inflammatory drugs inhibit the early lesion of diabetic retinopathy. Diabetes 56 (2007), 337–345.
43. Liu, X., Ye, F., Xiong, H., Hu, D.N., Limb, G.A., Xie, T., et al. IL-1b induces IL-6 production in retinal Müller cells predominantly through the activation of P38 MAPK/NF-kB signaling pathway. Exp Cell Res 331 (2015), 223–231.
44. Vincent, J.A., Mohr, S., Inhibition of caspase-1/interleukin-1β signaling prevents degeneration of retinal capillaries in diabetes and galactosemia. Diabetes 56 (2007), 224–230.
45. Haritoglou, C., Gerss, J., Sauerland, C., Kampik, A., Ulbig, M.W., Effect of calcium dobesilate on occurrence of diabetic macular oedema (CALDIRET study): randomised, double-blind, placebo-controlled, multicentre trial. Lancet 373 (2009), 1364–1371.
46. Klein, B.E., Overview of epidemiologic studies of diabetic retinopathy. Ophthalmic Epidemiol 14 (2007), 179–183.
47. Simó, R., Hernández, C., European Consortium for the Early Treatment of Diabetic Retinopathy (EUROCONDOR). Neurodegeneration in the diabetic eye, new insights and therapeutic perspectives. Trends Endocrinol Metab 25 (2014), 23–33.